Drugs / Modified anti-CD19 CAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04684472 | Mar 2021 → Jan 2023 | B-cell non-Hodgkin lymphoma, acute leukemia | Liqun Zou | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Modified anti-CD19 CAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04684472 ↗ |
| Modality | Cell therapy | “CAR T cell therapy” NCT04684472 ↗ |
| Route | Intravenous | “intravenous infusion” NCT04684472 ↗ |
| Target | CD19 | “Modified anti-CD19 CAR T cells” NCT04684472 ↗ |